Aiforia Technologies

1.95 EUR

0.00 %

2,203 following

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

0.00 %
+14.84 %
+4.84 %
-21.69 %
-24.42 %
-43.48 %
-47.86 %
-
-61.46 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
65.88M EUR
Turnover
85.35K EUR
P/E (adj.) (26e)
-7.87
EV/EBIT (adj.) (26e)
-8.14
P/B (26e)
4.86
EV/S (26e)
14.55
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.40 EUR
Updated
08.03.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 09.03.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
This hadn’t been posted here yet, @Antti_Siltanen interviews CEO Jukka Tapaninen: Aiforian kuulumiset: Foundation Enginellä nopeutta ja skaalautuvuutta tuotekehitykseen - Inderes
5/20/2026, 6:14 AM
by NukkeNukuttaja
21
Laakkonen flagged over 5%: Aiforia Technologies Oyj: Arvopaperimarkkinalain 9 luvun 10 pykälän mukainen ilmoitus omistusosuudesta - Mikko Laakkosen omistus Aiforia Technologies Oyj:ssä | Kauppalehti
5/18/2026, 2:04 PM
by NukkeNukuttaja
21
Antti & Antti Co have written comments regarding, among other things, how M&A activity in digital pathology is on the rise Consolidation in the digital pathology market took a step forward last week. The Swiss company Roche announced the acquisition of the US-based PathAI for a price...
5/15/2026, 5:22 AM
by Sijoittaja-alokas
21
In that video, Dr. Zuraw praises Aiforia starting at around the 12:30 mark. The case involves assisting Pakistani pathologist Zehra Talat, to which Aiforia responded when others did not. This is also good publicity for Aiforia.
5/20/2026, 3:13 AM
by Salvelinus
20
LinkedIn Development of convolutional neural networks for automated brain-wide... Speeding up image analysis time from weeks to minutes. ⏱️ That's how AI is transforming preclinical synucleinopathy research. Traditional characterization of histological samples in neurodegenerative...
5/22/2026, 7:58 AM
by Salvelinus
15
Grundium, a company emerging from the camera and computer vision hub in Hervanta, has acquired Aiforia’s competitor, Visiopharm. It seems that firms providing these machine learning models and software are now in high demand. Grundium – 21 May 26 Grundium Acquires Visiopharm to Create...
5/21/2026, 3:09 PM
by Loiskuttaja
15
The financial figures for unlisted companies are on very uncertain ground, so estimating valuation levels can easily go significantly wrong. A couple of comments: According to some sources (GrowJo, Zoominfo), PathAI’s revenue was ~100 MUSD. These should probably be taken with a fair...
5/19/2026, 7:53 AM
by Antti Siltanen
13
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.